Hetero launches generic favipiravir to treat Covid-19 in India - Pharmaceutical Technology
Favivir - Favipiravir Tablets used for Mild to Moderate Covid-19 Disease Patients
Dr. Reddy's launches Avigan tablets, priced at ₹99 each - The Hindu
A koronavírusos betegek kezelésében hatásos az időben megkezdett Favipiravir terápia
Avigan May Cause Birth Defects. Japan's Pushing It for Coronavirus. - The New York Times
Favipiravir only benefits recovery in younger patients hospitalised with COVID-19 - Hospital Pharmacy EuropeHospital Pharmacy Europe
Favipiravir Glenmark Fabiflu Tablet 200 Mg, Prescription, Treatment: Mild Covid 19
Favipiravir shows good clinical efficacy in treating COVID-19: official - Xinhua | English.news.cn
Favipiravirral bizniszeltek, bíróság elé kerültek mind a tizenhárman | 168.hu
Health Ministry Will Administer Favipiravir to All COVID-19 Patients
Favipiravir 200 mg Manufacturer, Supplier, Exporter
FAVIPIRAVIR TABLETS - Globela Pharma Pvt Ltd.
Govt. Stockpiles More Medicine for Treating
AA Medical Products Ltd.
Az OGYÉI a véleményüket vállalni merő kutatókat akarja elhallgattatni a Favipiravir-ügyben tett feljelentésével
Glenmark's FabiFlu approved for coronavirus treatment in India, costs Rs 103 per tablet - India Today
Index - Belföld - A háziorvos is felírhatja ezentúl a koronavírus-betegeknek a favipiravir tablettát
Avigan influenza antiviral to enter phase III trials in COVID-19 patients
Favipiravir as treatment for mild to moderate COVID-19 - Glenmark
Favilavir approved as experimental coronavirus drug
Cipla to launch favipiravir under Ciplenza in August at 68 rupees per pill | Mint
The Japanese Government Delivered 12200 Avigan Tablets For Treatment Of Covid 19 In Indonesia | Portal Kementerian Luar Negeri Republik Indonesia
Avigan 200mg Tablet: View Uses, Side Effects, Price and Substitutes | 1mg
Favipira (Favipiravir) - Beacon Pharmaceuticals PLC
Favipiravir to be investigated as a possible COVID-19 treatment for at-home recovery in the PRINCIPLE trial — Nuffield Department of Primary Care Health Sciences, University of Oxford
